Race and ethnicity and pharmacy dispensing of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetesResearch in context

Summary: Background: Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) and Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) improve cardiorenal outcomes in patients with type 2 diabetes. Equitable use of SGLT2i and GLP-1 RA has the potential to reduce racial and ethnic health disparities. We e...

Full description

Bibliographic Details

Published in:	The Lancet Regional Health. Americas
Main Authors:	Luis A. Rodriguez, Holly Finertie, Romain S. Neugebauer, Bennett Gosiker, Tainayah W. Thomas, Andrew J. Karter, Lisa K. Gilliam, Caryn Oshiro, Jaejin An, Gregg Simonson, Andrea E. Cassidy-Bushrow, Sarah Dombrowski, Margaret Nolan, Patrick J. O'Connor, Julie A. Schmittdiel
Format:	Article
Language:	English
Published:	Elsevier 2024-06-01
Subjects:	SGLT2i GLP-1 RA Type 2 diabetes Race and ethnicity Cardiovascular disease Renal disease
Online Access:	http://www.sciencedirect.com/science/article/pii/S2667193X24000863